Ovid Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Ovid Therapeutics de 39.5% y 47.6% por año respectivamente. Se prevé que el BPA crezca en un 42.1% al año. Se espera que la rentabilidad financiera sea de -1.3% en 3 años.

Información clave

27.0%

Tasa de crecimiento de los beneficios

32.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.7%
Tasa de crecimiento de los ingresos	46.5%
Rentabilidad financiera futura	-1.3%
Cobertura de analistas	Good
Última actualización	30 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:OVID - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	30	-55	-82	-73	4
12/31/2025	44	-30	-74	0	8
12/31/2024	11	-55	-80	-48	9
12/31/2023	0	-52	-46	-46	N/A
9/30/2023	0	-49	-43	-43	N/A
6/30/2023	0	-49	-46	-46	N/A
3/31/2023	0	-51	-49	-47	N/A
12/31/2022	2	-54	-57	-55	N/A
9/30/2022	1	-68	-60	-58	N/A
6/30/2022	1	-66	-58	-56	N/A
3/31/2022	1	-67	-63	-62	N/A
12/31/2021	208	120	118	119	N/A
9/30/2021	214	123	116	116	N/A
6/30/2021	221	117	125	126	N/A
3/31/2021	221	110	128	128	N/A
12/31/2020	13	-81	-52	-52	N/A
9/30/2020	7	-76	-54	-54	N/A
6/30/2020	N/A	-76	-62	-62	N/A
3/31/2020	N/A	-67	-57	-57	N/A
12/31/2019	N/A	-60	-51	-51	N/A
9/30/2019	N/A	-56	-45	-45	N/A
6/30/2019	N/A	-53	-46	-46	N/A
3/31/2019	N/A	-53	-46	-45	N/A
12/31/2018	N/A	-52	-46	-46	N/A
9/30/2018	N/A	-50	-44	-44	N/A
6/30/2018	N/A	-46	-43	-43	N/A
3/31/2018	N/A	-44	-37	-37	N/A
12/31/2017	N/A	-65	-32	-31	N/A
9/30/2017	N/A	-61	N/A	-28	N/A
6/30/2017	N/A	-58	N/A	-23	N/A
3/31/2017	N/A	-53	N/A	-21	N/A
12/31/2016	N/A	-22	N/A	-18	N/A
9/30/2016	N/A	-18	N/A	-14	N/A
12/31/2015	N/A	-13	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que OVID siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que OVID siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que OVID siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: OVID's revenue (46.5% per year) is forecast to grow faster than the US market (8.2% per year).

Ingresos de alto crecimiento: Se prevé que los ingresos (47.6% al año) de OVID crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: OVID se prevé que no sea rentable en 3 años.

Ovid Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 1,902%

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Consensus revenue estimates increase by 48%

Consensus revenue estimates increase by 14%

Price target increased by 7.1% to US$5.00

Recent updates

Ovid Therapeutics Inc., Annual General Meeting, Jun 06, 2024

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

President recently bought US$50k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus revenue estimates increase by 1,902%

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Consensus revenue estimates increase by 48%

Ovid Therapeutics Inc. Announces Changes to Its Board

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Consensus revenue estimates increase by 14%

Price target increased by 7.1% to US$5.00

Consensus revenue estimates increase by 60%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Ovid Therapeutics Doses Healthy Volunteers with OV329 in Phase 1 Trial

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2021)

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in 2Q 2021)

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Price target decreased to US$4.70

Ovid Therapeutics Inc., Annual General Meeting, Jun 09, 2022

Price target increased to US$5.50

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to US$5.50

President & Chief Medical Officer notifies of intention to sell stock

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 3000E Index

Treasurer & Corporate Controller Timothy Daly has left the company

Ovid Therapeutics: Good Entry Point For Investors

Ovid Therapeutics appoints Jeff Rona as CFO

Price target decreased to US$4.88

Investor sentiment improved over the past week

Price target decreased to US$5.40

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

New 90-day high: US$4.04

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

New 90-day low: US$2.42

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Analysts increase revenue estimates to US$11.1m

Ovid Therapeutics Inc. Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

Ovid Therapeutics misses goal in Angelman syndrome treatment

New 90-day high: US$6.84

Price target raised to US$14.67

Revenue beats expectations, earnings disappoint

New 90-day low: US$5.34

Ovid Therapeutics Inc. Announces Results from the Arcade and Endymion Studies of Soticlestat (Ov935/Tak-935) in Patients with Developmental and Epileptic Encephalopathies (Dees), or Rare Epilepsies

Ovid Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

New 90-day high - US$8.00

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Microcap Value Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento